
Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL
Zentalis Pharmaceuticals stock price today
Zentalis Pharmaceuticals stock price monthly change
Zentalis Pharmaceuticals stock price quarterly change
Zentalis Pharmaceuticals stock price yearly change
Zentalis Pharmaceuticals key metrics
Market Cap | 213.79M |
Enterprise value | N/A |
P/E | -3.84 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 2.33 |
PEG ratio | 0.11 |
EPS | -3.36 |
Revenue | N/A |
EBITDA | -178.49M |
Income | -218.90M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeZentalis Pharmaceuticals stock price history
Zentalis Pharmaceuticals stock forecast
Zentalis Pharmaceuticals financial statements
Jun 2023 | 0 | -112.52M | |
---|---|---|---|
Sep 2023 | 0 | -55.52M | |
Dec 2023 | 2.10M | -60.91M | -2895.29% |
Mar 2024 | 40.56M | 10.06M | 24.82% |
Mar 2024 | 40.56M | 10.06M | 24.82% |
---|---|---|---|
Sep 2025 | 0 | -57.32M | |
Oct 2025 | 40.56M | -65.67M | -161.92% |
Dec 2025 | 40.56M | -65.67M | -161.92% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 621444000 | 98.16M | 15.8% |
---|---|---|---|
Sep 2023 | 585715000 | 103.81M | 17.73% |
Dec 2023 | 562027000 | 124.63M | 22.18% |
Mar 2024 | 557479000 | 98.70M | 17.71% |
Jun 2023 | -79.27M | 72.93M | 236.62M |
---|---|---|---|
Sep 2023 | -38.66M | -117.45M | 309K |
Dec 2023 | -40.59M | -42.06M | 0 |
Mar 2024 | -51.97M | 61.54M | 7K |
Zentalis Pharmaceuticals alternative data
Aug 2023 | 156 |
---|---|
Sep 2023 | 156 |
Oct 2023 | 156 |
Nov 2023 | 156 |
Dec 2023 | 156 |
Jan 2024 | 156 |
Feb 2024 | 156 |
Apr 2024 | 124 |
May 2024 | 124 |
Jun 2024 | 124 |
Jul 2024 | 124 |
Zentalis Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Nov 2023 | 22000 | 0 |
Feb 2024 | 0 | 28862 |
May 2024 | 0 | 12953 |
Oct 2024 | 0 | 1603 |
Insider | Compensation |
---|---|
Dr. Anthony Y. Sun M.D. (1972) Pres, Chief Executive Officer & Executive Chairman | $957,280 |
Dr. Kevin D. Bunker Ph.D. (1973) Chief Operating Officer | $699,500 |
Ms. Alexis M. Pinto J.D. (1967) Chief Legal Officer & Sec. | $491,130 |
Mr. Cam S. Gallagher M.B.A. (1970) Sec. & Director | $467,150 |
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals: Azenosertib Continues To Impress
Doubling Down On Gain Therapeutics
Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way Off
Zentalis: A Buy As Small Molecule Trials Continue To Advance
Week In Review: China Life Science Posts $1.3 Billion In Deals
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
-
What's the price of Zentalis Pharmaceuticals stock today?
One share of Zentalis Pharmaceuticals stock can currently be purchased for approximately $1.59.
-
When is Zentalis Pharmaceuticals's next earnings date?
Unfortunately, Zentalis Pharmaceuticals's (ZNTL) next earnings date is currently unknown.
-
Does Zentalis Pharmaceuticals pay dividends?
No, Zentalis Pharmaceuticals does not pay dividends.
-
How much money does Zentalis Pharmaceuticals make?
Zentalis Pharmaceuticals has a market capitalization of 213.79M.
-
What is Zentalis Pharmaceuticals's stock symbol?
Zentalis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ZNTL".
-
What is Zentalis Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Zentalis Pharmaceuticals?
Shares of Zentalis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Zentalis Pharmaceuticals's key executives?
Zentalis Pharmaceuticals's management team includes the following people:
- Dr. Anthony Y. Sun M.D. Pres, Chief Executive Officer & Executive Chairman(age: 53, pay: $957,280)
- Dr. Kevin D. Bunker Ph.D. Chief Operating Officer(age: 52, pay: $699,500)
- Ms. Alexis M. Pinto J.D. Chief Legal Officer & Sec.(age: 58, pay: $491,130)
- Mr. Cam S. Gallagher M.B.A. Sec. & Director(age: 55, pay: $467,150)
-
How many employees does Zentalis Pharmaceuticals have?
As Jul 2024, Zentalis Pharmaceuticals employs 124 workers.
-
When Zentalis Pharmaceuticals went public?
Zentalis Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 3 Apr 2020.
-
What is Zentalis Pharmaceuticals's official website?
The official website for Zentalis Pharmaceuticals is zentalis.com.
-
Where are Zentalis Pharmaceuticals's headquarters?
Zentalis Pharmaceuticals is headquartered at 1359 Broadway, New York, NY.
-
How can i contact Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals's mailing address is 1359 Broadway, New York, NY and company can be reached via phone at +212 4333791.
Zentalis Pharmaceuticals company profile:

Zentalis Pharmaceuticals, Inc.
zentalis.comNASDAQ
124
Biotechnology
Healthcare
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
New York, NY 10018
CIK: 0001725160
ISIN: US98943L1070
CUSIP: 98943L107